莱伯泰科(688056) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 40 million and 43 million yuan, an increase of 12.4375 million to 15.4375 million yuan compared to the previous year, representing a year-on-year increase of 45.12% to 56.01%[4] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses is expected to be between 31.82 million and 34.82 million yuan, an increase of 8.5188 million to 11.5188 million yuan, reflecting a year-on-year increase of 36.56% to 49.43%[4] - The total profit for the previous year was 28.4345 million yuan, with a net profit attributable to shareholders of the parent company of 27.5625 million yuan[6] Revenue and Income - The company reported an increase in operating income of approximately 8 million yuan compared to 2023, with an overall product gross margin recovering from an average of 43.79% in 2023[8] - The company recognized government subsidy income that increased by 3.4331 million yuan compared to the same period last year[9] Expense Management - The company reduced the share-based payment expense by 6.5534 million yuan compared to 2023, with the current period's expense amounting to -454,600 yuan[8]